Skip to main content
. Author manuscript; available in PMC: 2023 May 2.
Published in final edited form as: Stroke. 2014 Feb 6;45(5):1545–1588. doi: 10.1161/01.str.0000442009.06663.48
Reviewer Employment Research Grant Other Research Support Speakers’ Bureau/Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other
Jo-Ann Eastwood University of California Los Angeles AHA None Preventive Cardiovascular Nurses: Expert exchange* None None None None
Michael D. Hill University of Calgary Covidien (money goes to institution); Hoffmann-La Roche Canada (money goes to institution) Heart & Stroke Foundation Alberta (money goes to institution); Alberta Innovates Health Solutions (money goes to institution) None None None Merck Ltd.* None
Marian Limacher University of Florida NIH None None None None None None
Virginia Miller Mayo Clinic None None None None None None None
Latha Stead University of Florida None None None None None None None
Greg Zipfel Washington University NINDS; AHA; Brain Aneurysm Foundation*; Hope Center for Neurological Disorders*; Pfizer None None None None Pfizer* None
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10000 or more during any 12-month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
Significant.